The HSP90 inhibitor, 17-allylamino-17-demethoxygeldanamycin (17-AAG) can cause a significant decrease in Axl protein levels in cell line and xenograft models, inhibiting EMT and tumour growth [105]. Here, AXL is linked to neoplasm.